These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 31297834)

  • 1. An investigation on the expression of miRNAs including miR-144 and miR-34a in plasma samples of RET-positive and RET-negative medullar thyroid carcinoma patients.
    Shabani N; Sheikholeslami S; Paryan M; Zarif Yeganeh M; Tavangar SM; Azizi F; Mohammadi-Yeganeh S; Hedayati M
    J Cell Physiol; 2020 Feb; 235(2):1366-1373. PubMed ID: 31297834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of miRNAs expression in medullary thyroid carcinoma tissue samples: miR-34a and miR-144 as promising overexpressed markers in MTC.
    Shabani N; Razaviyan J; Paryan M; Tavangar SM; Azizi F; Mohammadi-Yeganeh S; Hedayati M
    Hum Pathol; 2018 Sep; 79():212-221. PubMed ID: 29885402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients.
    Romeo P; Colombo C; Granata R; Calareso G; Gualeni AV; Dugo M; De Cecco L; Rizzetti MG; Zanframundo A; Aiello A; Carcangiu ML; Gloghini A; Ferrero S; Licitra L; Greco A; Fugazzola L; Locati LD; Borrello MG
    Endocr Relat Cancer; 2018 Mar; 25(3):217-231. PubMed ID: 29298817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome.
    Mian C; Pennelli G; Fassan M; Balistreri M; Barollo S; Cavedon E; Galuppini F; Pizzi M; Vianello F; Pelizzo MR; Girelli ME; Rugge M; Opocher G
    Thyroid; 2012 Sep; 22(9):890-6. PubMed ID: 22747440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.
    Chu YH; Lloyd RV
    Endocr Pathol; 2016 Dec; 27(4):312-324. PubMed ID: 27539727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [
    Wang Y; Du LL; Hou SH; Han CZ; Zhao XW; Wang WG; Xu XQ; Jing JX
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Nov; 51(11):873-876. PubMed ID: 27938622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
    Spitschak A; Meier C; Kowtharapu B; Engelmann D; Pützer BM
    Mol Cancer; 2017 Jan; 16(1):24. PubMed ID: 28122586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence of somatic RAS mutations in medullary thyroid cancer - a Polish population study.
    Oczko-Wojciechowska M; Pfeifer A; Rusinek D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Kowal M; Swierniak M; Krajewska J; Gawlik T; Chmielik E; Czarniecka A; Szpak-Ulczok S; Jarząb B
    Endokrynol Pol; 2015; 66(2):121-5. PubMed ID: 25931041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma.
    Bim LV; Navarro FCP; Valente FOF; Lima-Junior JV; Delcelo R; Dias-da-Silva MR; Maciel RMB; Galante PAF; Cerutti JM
    BMC Med Genomics; 2019 Jul; 12(1):104. PubMed ID: 31288802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.
    Hedayati M; Zarif Yeganeh M; Sheikholeslami S; Afsari F
    Crit Rev Clin Lab Sci; 2016 Aug; 53(4):217-27. PubMed ID: 26678667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RET Proto-oncogene Gene Mutation Is Related to Cervical Lymph Node Metastasis in Medullary Thyroid Carcinoma.
    Wang S; Wang B; Xie C; Ye D
    Endocr Pathol; 2019 Dec; 30(4):297-304. PubMed ID: 31494787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RET proto oncogene mutation detection and medullary thyroid carcinoma prevention.
    Yeganeh MZ; Sheikholeslami S; Hedayati M
    Asian Pac J Cancer Prev; 2015; 16(6):2107-17. PubMed ID: 25824727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification.
    Mian C; Pennelli G; Barollo S; Cavedon E; Nacamulli D; Vianello F; Negro I; Pozza G; Boschin IM; Pelizzo MR; Rugge M; Mantero F; Girelli ME; Opocher G
    Eur J Endocrinol; 2011 Jun; 164(6):971-6. PubMed ID: 21422198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of
    Pishkari S; Hadavi R; Koochaki A; Razaviyan J; Paryan M; Hashemi M; Mohammadi-Yeganeh S
    Horm Mol Biol Clin Investig; 2021 Mar; 42(3):265-271. PubMed ID: 33769725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PDCD4/miR-21 pathway in medullary thyroid carcinoma.
    Pennelli G; Galuppini F; Barollo S; Cavedon E; Bertazza L; Fassan M; Guzzardo V; Pelizzo MR; Rugge M; Mian C
    Hum Pathol; 2015 Jan; 46(1):50-7. PubMed ID: 25316501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma.
    Hudson J; Duncavage E; Tamburrino A; Salerno P; Xi L; Raffeld M; Moley J; Chernock RD
    Exp Mol Pathol; 2013 Aug; 95(1):62-7. PubMed ID: 23685355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas.
    Ramone T; Romei C; Ciampi R; Tacito A; Piaggi P; Torregrossa L; Ugolini C; Elisei R
    Endocrine; 2019 Sep; 65(3):623-629. PubMed ID: 31278686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
    Romei C; Ciampi R; Elisei R
    Nat Rev Endocrinol; 2016 Apr; 12(4):192-202. PubMed ID: 26868437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
    Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
    Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
    Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
    J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.